approach for the distalconstruction of a C(sp3)−SCF2R bond on aliphaticalcoholsenabled by 1,5-hydrogen-atom transfer (HAT) was developed. In the presence of a hypervalent iodine (PIDA) and readily available ArSO2SCF2R reagents, this transition metal-free approach allowed the remote functionalization of a broad variety of alcohols with emergent and high added-value SCF2R moieties (R=H, F, CO2Et and
开发了一种通过 1,5-氢原子转移 (HAT) 在脂肪醇上构建 C( sp 3 )-SCF 2 R 键的方法。在高价碘 (PIDA) 和现成的 ArSO 2 SCF 2 R 试剂存在的情况下,这种不含过渡金属的方法可以远程官能化具有新兴和高附加值 SCF 2 R 部分的多种醇(R= H、F、CO 2 Et 和 PO(OEt) 2 ) 在蓝光照射下。
2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles
申请人:Tsubouchi Hidetsugu
公开号:US20060094767A1
公开(公告)日:2006-05-04
The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula:
wherein R
1
represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R
2
represents a group —OR
3
or the like, and R
3
represents a hydrogen atom, C1-C6 alkyl group or the like, or R
1
and —(CH
2
)
n
R
2
may bind to each other together with carbon atoms adjacent thereto through nitrogen atoms so as to form a spiro ring represented by the general formula (H):
wherein R
41
is hydrogen, C1-C6 alkyl group or the like. The present compound has an excellent bactericidal action against
Mycobacterium tuberculosis
, multi-drug-resistant
Mycobacterium tuberculosis
, and atypical acid-fast bacteria.
The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immuno-suppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SIP receptors.
The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or S1P receptors.
2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis
申请人:Tsubouchi Hidetsugu
公开号:US20080119478A1
公开(公告)日:2008-05-22
The present invention provides a 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound represented by the following general formula: (1) in the above formula (1), R1 represents a hydrogen atom or C1-C6 alkyl group, n represents an integer of 0 to 6, R1 and —(CH2)
n
R2 may form a spiro ring represented by the formula (30) below, together with the adjacent carbon atom (in the formula below, RRR represents a piperidyl group which may have substituents on the piperidine ring), (30) and R2 represents a benzothiazolyloxy group, quinolyloxy group, pyridyloxy group or the like. The present compound has an excellent bactericidal action against
Mycobacterium tuberculosis
, multi-drug-resistant
Mycobacterium tuberculosis
, and atypical acid-fast bacteria.